Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy
Anticancer Research · 2024
DOI: 10.21873/anticanres.17267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Michele Dionese und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit 1, Istituto Oncologico Veneto, IOV - IRCCS, Padua, Italy. Hauptthemen laut MEDLINE: Inflammation, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Unit 1, Istituto Oncologico Veneto, IOV - IRCCS, Padua, Italy.
- Oncology Unit, AULSS6 Euganea, Ospedali Riuniti Padova Sud, Monselice, Italy.
- Oncology Unit 1, Istituto Oncologico Veneto, IOV - IRCCS, Padua, Italy; davide.bimbatti@iov.veneto.it.
- Oncology Unit 3, Istituto Oncologico Veneto, IOV - IRCCS, Padua, Italy.
- Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy.
Zitieren
APA
Dionese, M., Bimbatti, D., Pierantoni, F., Lai, E., Erbetta, E., Cavasin, N., Jubran, S., Basso, U., & Maruzzo, M. (2024). Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy. Anticancer Research. https://doi.org/10.21873/anticanres.17267
Vancouver
Dionese M, Bimbatti D, Pierantoni F, Lai E, Erbetta E, Cavasin N, et al. Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy. Anticancer Research. 2024. doi:10.21873/anticanres.17267
BibTeX
@article{Dionese2024,
author = {Dionese, Michele and Bimbatti, Davide and Pierantoni, Francesco and Lai, Eleonora and Erbetta, Elisa and Cavasin, Nicolò and Jubran, Salim and Basso, Umberto and Maruzzo, Marco},
title = {Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17267}
}
EUVIMED